IL-17 markedly augments production of proangiogenic factors of tumors
| Angiogenic factors . | MCA205 . | MCA205 + IL-17* . | MCA205 + IL-17 + mAb . | MC38 . | MC38 + IL-17 . | MC38 + IL-17 + mAb . |
|---|---|---|---|---|---|---|
| VEGF | 5.87 ± 0.25 | 9.88 ± 0.67 | 5.75 ± 0.37 | 2.26 ± 0.13 | 2.7 ± 0.24 | 2.25 ± 0.18 |
| KC | 1.6 ± 0.13 | 29.26 ± 1.76 | 1.57 ± 0.17 | 0.36 ± 0.07 | 6.1 ± 0.5* | 0.38 ± 0.1 |
| MIP-2 | 10.0 ± 0.4 | 65.0 ± 4.2 | 11.0 ± 0.7 | 11.0 ± 0.8 | 78.0 ± 3.3* | 12.1 ± 0.7 |
| PGE1 | 27.5 ± 2.04 | 67.0 ± 4.49 | 27.7 ± 1.77 | 2.2 ± 0.12 | 4.5 ± 0.3* | 2.3 ± 0.15 |
| PGE2 | 9.0 ± 1.22 | 23.1 ± 3.67 | 10.1 ± 1.7 | 3.0 ± 0.41 | 5.8 ± 0.49* | 2.78 ± 0.57 |
| NO | 0.05 ± 0.01 | 0.09 ± 0.01 | 0.06 ± 0.01 | 0.95 ± 0.04 | 2.98 ± 0.58* | 0.97 ± 0.05 |
| Angiogenic factors . | MCA205 . | MCA205 + IL-17* . | MCA205 + IL-17 + mAb . | MC38 . | MC38 + IL-17 . | MC38 + IL-17 + mAb . |
|---|---|---|---|---|---|---|
| VEGF | 5.87 ± 0.25 | 9.88 ± 0.67 | 5.75 ± 0.37 | 2.26 ± 0.13 | 2.7 ± 0.24 | 2.25 ± 0.18 |
| KC | 1.6 ± 0.13 | 29.26 ± 1.76 | 1.57 ± 0.17 | 0.36 ± 0.07 | 6.1 ± 0.5* | 0.38 ± 0.1 |
| MIP-2 | 10.0 ± 0.4 | 65.0 ± 4.2 | 11.0 ± 0.7 | 11.0 ± 0.8 | 78.0 ± 3.3* | 12.1 ± 0.7 |
| PGE1 | 27.5 ± 2.04 | 67.0 ± 4.49 | 27.7 ± 1.77 | 2.2 ± 0.12 | 4.5 ± 0.3* | 2.3 ± 0.15 |
| PGE2 | 9.0 ± 1.22 | 23.1 ± 3.67 | 10.1 ± 1.7 | 3.0 ± 0.41 | 5.8 ± 0.49* | 2.78 ± 0.57 |
| NO | 0.05 ± 0.01 | 0.09 ± 0.01 | 0.06 ± 0.01 | 0.95 ± 0.04 | 2.98 ± 0.58* | 0.97 ± 0.05 |
Cells (1 × 105/mL) were cultured for 48 hours with or without 50 ng/mL IL-17 or 50 ng/mL IL-17 plus 20 μg/mL neutralizing antimouse IL-17 mAb. Cell-free supernatants were collected and assayed for the concentrations of VEGF, KC, MIP-2, PGE1, PGE2, and NO (ng/mL for VEGF, KC, PGE1, and PGE2; pg/mL for MIP-2; μM for NO). Data were expressed as mean ± SD (n = 3 per data point).
P < .05.